ASCO 2024 Highlights

Wednesday, July 3, 2024

ASCO 2024 Dr. Barve

MCCR Chief Medical Officer, Dr. Minal Barve at ASCO 2024

The American Society of Clinical Oncology (ASCO) held its 60th Annual Meeting in Chicago from May 31 to June 4, 2024, with more than 40,000 attendees from around the globe including both clinicians and professionals.

The meeting featured hundreds of sessions uplifting the theme of “The Art and Science of Cancer Care: From Comfort to Cure.” Thousands of abstracts, posters, publications and educational sessions were presented during the ASCO 2024 Annual Meeting, including several by Mary Crowley Cancer Research.

MCCR staff members and physicians had the opportunity to meet with representatives from more than 20 organizations including several key industry companies, patient advocacy groups and patient foundations. These meetings will be invaluable in exploring new collaborative opportunities for Mary Crowley Cancer Research.

MCCR contributed many abstract posters and four were selected for oral presentation. Review Mary Crowley Cancer Research’s contributions in abstracts, posters, presentations and videos, by clicking on the links below:

Dr. Minal Barve’s Contributions
Trial 19-09 – Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Trial 21-46 – Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC).

Trial 20-17 – Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies.

Trial 21-25 – Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.

Trial 23-22 – First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.

Trial 20-13 – A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.

Trial 21-39 – Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

Trial 20-13 – Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.

Trial 20-06 – Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.

Trial 22-09 – A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

Trial 22-14 – Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.

Trial 22-26 – A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).

Dr. Douglas Orr’s Contributions
Trial 23-08 – Safety and activity of Diakine DK210 (EGFR), a next-generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.

Trial 21-40 – Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.

Dr. Reva Schneider’s Contributions

Trial 23-05 – Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).

The Mary Crowley Cancer Research team thanks all our patients, caregivers, staff members and referring oncologists for supporting MCCR and contributing to clinical research. Without the patients’ commitment, there would not be such amazing advances to share at conferences such as ASCO. HOPE LIVES HERE!